CoChat
Sign Up
Cited by 264Lipoproteins and Cardiovascular HealthCancer, Lipids, and MetabolismPharmacovigilance and Adverse Drug Reactions

The DOI matches its Crossref record; 201 of the 205 references it cites were found in a registry or an index.

Statin Safety: An Overview and Assessment of the Data—2005

Bays, Harold·2006·The American Journal of Cardiology
DOI 10.1016/j.amjcard.2005.12.006
Open this paper in CoChat — free account

Abstract

The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statin drugs, have been studied in numerous controlled human research trials involving hundreds of thousands of study participants. Statins have been prescribed for millions of patients. Based on this vast research and clinical experience, statins have been shown to improve lipid blood levels and reduce atherosclerotic coronary artery disease (CAD) risk, resulting in reduced CAD morbidity and mortality, and in several studies, reduced overall ("all-cause") mortality. From a safety perspective, both research trial evidence and clinical practice experience have demonstrated that statins are generally well tolerated. However, as with all pharmaceuticals, safety considerations exist with both monotherapy and combination statin therapy, mainly involving potential adverse effects on muscle, liver, kidney, and the nervous system. The evidence supporting statin-related potential adverse experiences on these organ systems is sometimes strong and based on clear clinical trial evidence (such as the increased risk of muscle enzyme elevation with higher statin doses). The evidence is at other times more speculative, being based on case reports and inconclusive clinical trial data (such as possible favorable or unfavorable effects of statins on cognition). Because the use of statins is so widespread, it is useful for the clinician to understand statin safety issues and the level of available evidence supporting the contention that various adverse effects are caused by statins. This review presents an assessment of statin safety based on an overview of the current statin safety data and their clinical implications.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.amjcard.2005.12.006

Cites

201 of 201 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

4 of the 205 references couldn’t be matched to a known paper.

Research works printed but not linked: 9

  1. Bottorff, 2004, Safety and statins, Am J Manag Care, 4, S27
  2. 2005, Position Statement, Diabetes Care, 28, S4
  3. Bays, 2003, Colesevelam HCl, Expert Opin Pharmacother, 4, 779
  4. Evans, 2004, Statin safety in perspective—maximising the risk:benefit, British Journal of Cardiology, 11, 449
  5. Bays, 2003, Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]), Am J Cardiol, 91, 667, 10.1016/S0002-9149(03)00007-9 · DOI
  6. Omar, 2002, FDA adverse event reports on statin-associated rhabdomyolysis, Ann Pharmacother, 36, 288, 10.1345/aph.1A289 · DOI · Paper page
  7. Davidson, 2000, Lipid-altering efficacy and safety of simvastatin 80 mg/day, Nutr Metab Cardiovasc Dis, 10, 253
  8. 1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease, Lancet, 344, 1383
  9. Eckernas, 1993, The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep, Br J Clin Pharmacol, 35, 284

Cited by

Sorted by citations

See all 264

Related

See all

Metadata

Authors
Bays, H.
Affiliations
Louisville Metabolic and Atherosclerosis Research Center (US)
Corresponding author
Bays, Harold
ORCID
Bays, Harold
Venue
The American Journal of Cardiology
Publisher
Elsevier BV
Published
2006-04
Volume
97
Issue
8
Pages
S6-S26
ISSN
0002-9149 (ISSN-L)
DOI
10.1016/j.amjcard.2005.12.006
OpenAlex
W2011527537
Cited by
264
References
205
Citations by year
2026: 3 · 2025: 3 · 2024: 3 · 2023: 3 · 2022: 7 · 2021: 6 · 2020: 10 · 2019: 10 · 2018: 12 · 2017: 19 · 2016: 17 · 2015: 11 · 2014: 17 · 2013: 15 · 2012: 12
FWCI
5.20
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The American Journal of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords
statins, drug safety, adverse drug reactions, rhabdomyolysis, elevated liver enzymes, renal function, cognitive effects, lipid-lowering therapy, coronary artery disease, all-cause mortality
MeSH terms
Hypolipidemic Agents, Dementia, Dose-Response Relationship, Drug, Drug Therapy, Combination, Humans, Kidney Diseases, Liver, Muscular Diseases, Peripheral Nervous System Diseases, Proteinuria, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Evidence-Based Medicine, Stroke, Chemical and Drug Induced Liver Injury

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review